Boston Scientific
BSX stock analysis · Health Care · Health Care Equipment
As of · fund-implied per-share value
Fund holding value ÷ shares held. Not a live quote; not adjusted for later stock splits.
View SEC fund filing ↗Price × SEC outstanding shares. Shares measured 2026-04-29. Approximate; share and price dates can differ.
View share-count filing ↗Reviewed debt balance
Reviewed consolidated balance-sheet debt: current debt 299000000 plus noncurrent debt 11137000000, in USD. Includes current borrowings/current maturities already reported in the current debt line; current borrowings are included once in the capital calculation. Uses debt carrying amounts as presented, including financing leases only where included by the issuer; excludes operating leases and trade/insurance liabilities. This is a book-capital proxy, not fair value or a claim that every other liability is financing debt. Applies only to this reviewed fiscal period. Read the financial statement ↗
DCF value
Equity cash-flow scenario · SEC outstanding shares at 2026-04-29 · -12.4% versus input cap
How this is calculated ↗Reverse DCF
Annual basis · read assumptions below
How this is calculated ↗Relative valuation
14 industry peers · median 28.3×
How this is calculated ↗Historical multiples
6 annual observations · snapshot P/E 21.9× · -69.5% versus history
How this is calculated ↗Free cash flow yield
Annual basis · read assumptions below
How this is calculated ↗ROIC / quality
Normalized tax · financing-capital proxy
How this is calculated ↗Value composite
Annual basis · read assumptions below
How this is calculated ↗12–1 price momentum
Split and corporate-action verification is incomplete for these fund observations. Verified adjusted endpoints are required for 12–1 momentum.
How this is calculated ↗Asset growth
Annual basis · read assumptions below
How this is calculated ↗Net payout yield
Requires reported dividends, repurchases and issuance; missing values are not zero.
How this is calculated ↗Accrual quality
Annual basis · read assumptions below
How this is calculated ↗Fundamental momentum
Annual basis · read assumptions below
How this is calculated ↗Follow the cash
ANNUAL · USDOperating cash flow and reinvestment over time
Annual USD. Negative bars use a compressed lower scale. Hover or inspect the financial history table for exact values.
Make the assumptions yours
How sensitive is the valuation?
| Return / Growth | 3.0% | 5.0% | 7.0% |
|---|---|---|---|
| 8.0% | $46.88 | $51.16 | $55.75 |
| 10.0% | $34.36 | $37.38 | $40.63 |
| 12.0% | $27.11 | $29.41 | $31.88 |
Annual financial history
Open SEC filings ↗| Fiscal year-end | Revenue | Net income | Operating cash flow | Capital expenditure | Assets |
|---|---|---|---|---|---|
| 2025-12-31 | 20.1B | 2.9B | 4.5B | 876M | 43.7B |
| 2024-12-31 | 16.7B | 1.8B | 3.4B | 790M | 39.4B |
| 2023-12-31 | 14.2B | 1.6B | 2.5B | 711M | 35.1B |
| 2022-12-31 | 12.7B | 698M | 1.5B | 588M | 32.5B |
| 2021-12-31 | 11.9B | 1B | 1.9B | 554M | 32.2B |
| 2020-12-31 | 9.9B | -82M | 1.5B | 376M | 30.8B |
| 2019-12-31 | 10.7B | 4.7B | 1.8B | 461M | 30.6B |
| 2018-12-31 | 9.8B | 1.7B | 310M | 316M | 21B |
USD, abbreviated. Restated annual history; not a point-in-time backtest. Missing values appear as dashes.
Trace the inputs
MODEL ANNUAL PERIOD| Input | Value | SEC tag / source | Filed |
|---|---|---|---|
| revenue | 20.1B | RevenueFromContractWithCustomerExcludingAssessedTax | 2026-02-17 |
| netIncome | 2.9B | ProfitLoss Explicit consolidated amount, including the portion attributable to noncontrolling interests. | 2026-02-17 |
| Parent/common earnings proxy | 2.9B | NetIncomeLossAvailableToCommonStockholdersBasic | 2026-02-17 |
| cfo | 4.5B | NetCashProvidedByUsedInOperatingActivities | 2026-02-17 |
| capex | 876M | PaymentsToAcquirePropertyPlantAndEquipment | 2026-02-17 |
| operatingIncome | 3.6B | OperatingIncomeLoss | 2026-02-17 |
| assets | 43.7B | Assets | 2026-02-17 |
| equity | 24.5B | StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Explicit consolidated amount, including the portion attributable to noncontrolling interests. | 2026-02-17 |
| Parent book equity proxy | 24.2B | StockholdersEquity | 2026-02-17 |
| debt | 11.4B | Reviewed manual correction Reviewed consolidated balance-sheet debt: current debt 299000000 plus noncurrent debt 11137000000, in USD. Includes current borrowings/current maturities already reported in the current debt line; current borrowings are included once in the capital calculation. Uses debt carrying amounts as presented, including financing leases only where included by the issuer; excludes operating leases and trade/insurance liabilities. This is a book-capital proxy, not fair value or a claim that every other liability is financing debt. Applies only to this reviewed fiscal period. | 2026-02-17 |
| shortDebt | — | Not reported under a supported tag | — |
| cash | 2B | CashAndCashEquivalentsAtCarryingValue | 2026-02-17 |
| shares | 1.5B | WeightedAverageNumberOfDilutedSharesOutstanding | 2026-02-17 |
| dividends | — | Not reported under a supported tag | — |
| buybacks | — | Not reported under a supported tag | — |
| issuance | 282M | Reviewed manual correction Bounded FY2025-12-31 consolidated financing-statement extraction. Proceeds from issuances of shares of common stock pursuant to employee stock compensation and purchase plans: 282000000 USD [us-gaap:ProceedsFromStockPlans]. All 8 financing lines reconcile exactly to reported financing cash flow -395000000 USD. Cash inflows from common shares, employee plans and option exercises are summed once as displayed on the statement; noncash compensation, withholding payments, preferred and noncontrolling interests are excluded. This review applies only to this issuer and fiscal period. Source limitation: the statement also aggregates other financing cash flows (net 7000000 USD). Their common-equity portion is not separately disclosed here. Issuance is the sum of separately reported common cash-issuance lines, not an independently verified gross total; additional equity flows may be inside those aggregates. | 2026-02-17 |